candesartan has been researched along with Chronic Kidney Diseases in 10 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to investigate whether withaferin A treatment ameliorates the development of renal fibrosis and its related mechanisms in a CKD mouse model." | 7.96 | Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction. ( Chen, CM; Chiang, CK; Chung, YP; Guan, SS; Huang, KT; Liu, CH; Liu, SH; Wu, CT, 2020) |
| "Elastin deficiency causes vascular stiffening, a leading risk for hypertension and chronic kidney disease (CKD)." | 7.85 | Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling. ( Jie, L; Osei-Owusu, P; Owens, EA; Reyes, BAS; Van Bockstaele, EJ, 2017) |
| "Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood." | 7.01 | Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial. ( Eriguchi, M; Fujisaki, K; Kitazono, T; Nakano, T; Suehiro, T; Tanaka, S; Torisu, K; Tsuchimoto, A; Tsujikawa, H; Tsuruya, K; Yamada, S; Yoshida, H, 2021) |
| "We aimed to investigate whether withaferin A treatment ameliorates the development of renal fibrosis and its related mechanisms in a CKD mouse model." | 3.96 | Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction. ( Chen, CM; Chiang, CK; Chung, YP; Guan, SS; Huang, KT; Liu, CH; Liu, SH; Wu, CT, 2020) |
| "Elastin deficiency causes vascular stiffening, a leading risk for hypertension and chronic kidney disease (CKD)." | 3.85 | Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling. ( Jie, L; Osei-Owusu, P; Owens, EA; Reyes, BAS; Van Bockstaele, EJ, 2017) |
| "Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood." | 3.01 | Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial. ( Eriguchi, M; Fujisaki, K; Kitazono, T; Nakano, T; Suehiro, T; Tanaka, S; Torisu, K; Tsuchimoto, A; Tsujikawa, H; Tsuruya, K; Yamada, S; Yoshida, H, 2021) |
| " Candesartan in combination with RDN prolonged trough BP and attenuated renal hemodynamic responses to blood loss." | 1.72 | Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage. ( Booth, LC; Denton, KM; Head, GA; May, CN; McArdle, Z; Moritz, KM; Schlaich, MP; Singh, RR, 2022) |
| "The metabolic syndrome is a risk factor for the development of chronic kidney disease." | 1.35 | Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. ( Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, RR | 1 |
| McArdle, Z | 1 |
| Booth, LC | 1 |
| May, CN | 1 |
| Head, GA | 1 |
| Moritz, KM | 1 |
| Schlaich, MP | 1 |
| Denton, KM | 1 |
| Yamamura-Miyazaki, N | 1 |
| Michigami, T | 1 |
| Satomura, K | 1 |
| Urushihara, M | 1 |
| Kagami, S | 1 |
| Yamamoto, K | 1 |
| Chen, CM | 1 |
| Chung, YP | 1 |
| Liu, CH | 1 |
| Huang, KT | 1 |
| Guan, SS | 1 |
| Chiang, CK | 1 |
| Wu, CT | 1 |
| Liu, SH | 1 |
| Suehiro, T | 1 |
| Tsuruya, K | 2 |
| Yoshida, H | 2 |
| Tsujikawa, H | 1 |
| Yamada, S | 1 |
| Tanaka, S | 1 |
| Tsuchimoto, A | 1 |
| Eriguchi, M | 1 |
| Fujisaki, K | 1 |
| Torisu, K | 1 |
| Nakano, T | 1 |
| Kitazono, T | 1 |
| Owens, EA | 1 |
| Jie, L | 1 |
| Reyes, BAS | 1 |
| Van Bockstaele, EJ | 1 |
| Osei-Owusu, P | 1 |
| Cechova, S | 1 |
| Dong, F | 1 |
| Chan, F | 1 |
| Kelley, MJ | 1 |
| Ruiz, P | 1 |
| Le, TH | 1 |
| Kato, H | 1 |
| Shiraishi, T | 1 |
| Ueda, S | 1 |
| Kubo, E | 1 |
| Shima, T | 1 |
| Nagura, M | 1 |
| Yano, H | 1 |
| Izumikawa, Y | 1 |
| Shimada, M | 1 |
| Tomioka, S | 1 |
| Nosaka, H | 1 |
| Kojima, K | 1 |
| Tanemoto, M | 1 |
| Uchida, S | 1 |
| Namikoshi, T | 1 |
| Tomita, N | 1 |
| Satoh, M | 1 |
| Haruna, Y | 1 |
| Kobayashi, S | 1 |
| Komai, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Frimodt-Møller, M | 1 |
| Kamper, AL | 1 |
| Strandgaard, S | 1 |
| Kreiner, S | 1 |
| Nielsen, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study[NCT00235287] | Phase 4 | 60 participants (Anticipated) | Interventional | 2005-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for candesartan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antineoplastic Combined Chemotherapy Protocols; Benzimidazo | 2021 |
Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease--a randomized trial.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2012 |
8 other studies available for candesartan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2022 |
Reduction in urinary angiotensinogen levels and improvement of proteinuria by renin-angiotensin system blockade in pediatric chronic kidney disease patients with very low birth weight.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Benzimidazoles; Biomarkers; Bi | 2020 |
Withaferin A protects against endoplasmic reticulum stress-associated apoptosis, inflammation, and fibrosis in the kidney of a mouse model of unilateral ureteral obstruction.
Topics: Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Endoplasmic Reticulu | 2020 |
Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2017 |
Topics: Actins; Albuminuria; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Comp | 2018 |
Brain Atrophy and Cognitive Impairment in Chronic Kidney Disease.
Topics: Animals; Atrophy; Benzimidazoles; Biphenyl Compounds; Brain; Cognitive Dysfunction; Cyclic N-Oxides; | 2018 |
Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Benzimidazoles; Benzoa | 2015 |
Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dietary Protei | 2008 |